Medication info
Glyact Tablets (Pioglitazone Hydrochloride)

Glyact Tablets (Pioglitazone Hydrochloride)

Prescription medicationTabletOral
Ingredient · strength
Pioglitazone Hydrochloride›16.53mg / 1 tablet
Manufacturer / importer
Myungmoon Pharmaceutical Co., Ltd.
Appearance
White to grayish-white, convex cylindrical tablets
Packaging
30 tablets/bottle
Approval status
Active

MFDS item code 200704960 · Notified 2007.04.30 · Insurance code 649800040

Summary

Main use
Improvement of glycemic control in type 2 diabetes mellitus
Who takes it
Adults · Children
Adult dose
Administer this medicine orally once daily, regardless of meals. Diabetes management should be individualized. Ideally, the response to treatment should be evaluated by monitoring glycated hemoglobin (HbA1c), a more accurate diagnostic measure than fasting blood glucose (FBG). Glycated hemoglobin reflects blood glucose status over the previous 2 ~ 3 months. In clinical practice, if glycemic control in a patient with diabetes is not worsening, this medicine should be administered for a period adequate to assess changes in glycated hemoglobin (at least 3 months). 1. Monotherapy This medicine may be initiated as monotherapy at 15 mg of pioglitazone once daily in patients whose blood glucose is not adequately controlled by diet and exercise. If the initial dose of this medicine does not provide sufficient efficacy, the dose may be increased to 30 mg once daily. Combination therapy should be considered in patients who do not respond adequately to monotherapy. 2. Combination therapy 1) Sulfonylureas: This medicine may be administered in combination with a sulfonylurea; the initial dose is 15 mg once daily. When used in combination with this medicine, the current sulfonylurea may be continued at the same dose and regimen. However, if the patient develops symptoms of hypoglycemia, the sulfonylurea dose should be reduced. 2) Metformin: This medicine may be administered in combination with metformin; the initial dose is 15 mg once daily. When used in combination with this medicine, the current metformin may be continued at the same dose and regimen. It is unlikely that the metformin dose will need to be adjusted because of hypoglycemia during combination therapy with this medicine. 3) Insulin: This medicine may be administered in combination with insulin at a dose of 15 mg once daily. The current insulin dose may be maintained when combination therapy with this medicine is initiated. However, if a patient receiving this medicine in combination with insulin develops symptoms of hypoglycemia or the plasma glucose concentration decreases to 100 mg/dL or below, the insulin dose may be reduced by 10 ~ 25 %. Subsequent dose adjustments should be individualized according to glycemic control. • Maximum recommended dose For monotherapy or combination therapy with a sulfonylurea, metformin, or insulin, doses exceeding 30 mg once daily are not recommended. Dose adjustment is not recommended in patients with renal impairment (see the Precautions section, Patients with renal impairment). Do not initiate therapy with this medicine if, at the start of treatment, the patient has clinical evidence of active liver disease or increased serum aminotransferase levels (at least 2.5 times the upper limit of normal for ALT) (see Adverse Reactions and Precautions, Effects on the liver). Liver enzyme monitoring is recommended in all patients before starting therapy with this medicine and periodically thereafter. There are no data on the use of this medicine in combination therapy with another thiazolidinedione.
Child dose
Use is not recommended in children under 18 years of age because there is no experience with use in this age group.

Ingredients

Manufacturer
Myungmoon Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in type 2 diabetes mellitus

  • Type 2 diabetes
View approved original text

This medication is an adjunct to diet and exercise to help control blood sugar in patients with type 2 diabetes. It can be used alone, but if other oral hypoglycemic agents are ineffective, it can be combined with sulfonylureas, metformin, or insulin. Additionally, patients with type 2 diabetes should undergo nutritional counseling, weight loss, and regular exercise, as these efforts are very important for maintaining the effectiveness of the medication. This drug is used to improve blood sugar control.

How to take

Adult dose

Administer this medicine orally once daily, regardless of meals. Diabetes management should be individualized. Ideally, the response to treatment should be evaluated by monitoring glycated hemoglobin (HbA1c), a more accurate diagnostic measure than fasting blood glucose (FBG). Glycated hemoglobin reflects blood glucose status over the previous 2 ~ 3 months. In clinical practice, if glycemic control in a patient with diabetes is not worsening, this medicine should be administered for a period adequate to assess changes in glycated hemoglobin (at least 3 months). 1. Monotherapy This medicine may be initiated as monotherapy at 15 mg of pioglitazone once daily in patients whose blood glucose is not adequately controlled by diet and exercise. If the initial dose of this medicine does not provide sufficient efficacy, the dose may be increased to 30 mg once daily. Combination therapy should be considered in patients who do not respond adequately to monotherapy. 2. Combination therapy 1) Sulfonylureas: This medicine may be administered in combination with a sulfonylurea; the initial dose is 15 mg once daily. When used in combination with this medicine, the current sulfonylurea may be continued at the same dose and regimen. However, if the patient develops symptoms of hypoglycemia, the sulfonylurea dose should be reduced. 2) Metformin: This medicine may be administered in combination with metformin; the initial dose is 15 mg once daily. When used in combination with this medicine, the current metformin may be continued at the same dose and regimen. It is unlikely that the metformin dose will need to be adjusted because of hypoglycemia during combination therapy with this medicine. 3) Insulin: This medicine may be administered in combination with insulin at a dose of 15 mg once daily. The current insulin dose may be maintained when combination therapy with this medicine is initiated. However, if a patient receiving this medicine in combination with insulin develops symptoms of hypoglycemia or the plasma glucose concentration decreases to 100 mg/dL or below, the insulin dose may be reduced by 10 ~ 25 %. Subsequent dose adjustments should be individualized according to glycemic control. • Maximum recommended dose For monotherapy or combination therapy with a sulfonylurea, metformin, or insulin, doses exceeding 30 mg once daily are not recommended. Dose adjustment is not recommended in patients with renal impairment (see the Precautions section, Patients with renal impairment). Do not initiate therapy with this medicine if, at the start of treatment, the patient has clinical evidence of active liver disease or increased serum aminotransferase levels (at least 2.5 times the upper limit of normal for ALT) (see Adverse Reactions and Precautions, Effects on the liver). Liver enzyme monitoring is recommended in all patients before starting therapy with this medicine and periodically thereafter. There are no data on the use of this medicine in combination therapy with another thiazolidinedione.

Child dose

Use is not recommended in children under 18 years of age because there is no experience with use in this age group.

Precautions

This medication is used for the treatment of type 2 diabetes and helps control blood sugar by improving insulin resistance. However, it may put a strain on the heart in some patients, and should not be used in patients with heart failure or a history of heart failure. While taking this medication, patients should be closely monitored for sudden weight gain or symptoms of heart failure such as shortness of breath, and consult a doctor immediately if these symptoms occur. Also, this drug may cause fluid retention leading to edema, so it should be used with caution in patients who have edema. This medication should not be administered to patients with active bladder cancer or a history of bladder cancer, and any symptoms of hematuria or urinary problems during treatment should be reported to a doctor immediately. Patients with poor liver function or severe kidney impairment also require caution when taking this drug, and regular liver function tests and kidney function tests should be conducted. Women who are pregnant or may become pregnant are advised not to use this medication, and premenopausal women may need appropriate contraception as it can stimulate ovulation. There is an increased risk of hypoglycemia when this medication is used in combination with other hypoglycemic agents or insulin, so patients should be well aware of hypoglycemia symptoms and may need to adjust the doses of other medications if necessary. Elderly patients, those with poor nutritional status, patients engaged in vigorous exercise, and those with excessive alcohol consumption should also exercise caution for the risk of hypoglycemia. Regular blood glucose and liver function tests should be conducted during treatment, and it is important to inform healthcare personnel of any unusual symptoms. Finally, this medication is not recommended for children as safety and efficacy have not been established.

Side effects

Congestive heart failure, excessive and rapid weight changes, dyspnea, edema, fluid retention, inadequate blood sugar control, upper respiratory infection, headache, sinusitis, myalgia, pharyngitis, abdominal distension, weight gain, hypoglycemia, urinary tract infection, back pain, dizziness, diarrhea, elevated serum creatine kinase, hypertension, heart failure, limb pain, chest pain, mortality due to cardiovascular factors, exacerbation of congestive heart failure, emergency room visits due to congestive heart failure, fractures, diabetic macular edema accompanied by reduced vision, fatal and non-fatal liver failure, decreased hemoglobin, decreased hematocrit, elevated serum ALT levels, elevated serum bilirubin levels, visible hematuria, urinary disorders, urgency, fatigue, decreased appetite, discomfort in the right upper abdomen, dark urine, jaundice, anorexia, constipation, upper abdominal pain, chest pain, weakness, indigestion, nausea, itching, chest discomfort, tremors, chills, gastrointestinal diseases, abdominal pain, epigastric discomfort, numbness, muscle rigidity, head discomfort, increased liver enzymes, worsening liver disease, urticaria, eczema, arthralgia, knee abnormalities, arm weakness, proteinuria, increased serum creatinine, anxiety, insomnia, drowsiness, simple herpes, blurred vision, orthostatic hypotension, palpitations, stroke, sexual dysfunction, myocardial infarction

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be kept in a container that is protected from light and air. It is also advisable to avoid humid areas and store at a cool place between 15 to 30 degrees Celsius.

Appearance and packaging

Appearance

White to grayish-white, convex cylindrical tablets

Package unit

30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.